HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

TNF-Related Apoptosis-Inducing Ligand Receptors

Subscribe to New Research on TNF-Related Apoptosis-Inducing Ligand Receptors

Tumor necrosis factor receptor family members that are widely expressed and play a role in regulation of peripheral immune responses and APOPTOSIS. The receptors are specific for TNF-RELATED APOPTOSIS-INDUCING LIGAND and signal via conserved death domains that associate with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM.

Also Known As:

Receptors, TNF-Related Apoptosis-Inducing Ligand; APO2 Receptor; DCR2 Receptor; DR4 Receptor; DR5 Receptor; Death Receptor-4; Death Receptor-5; Receptor, TRAIL-1; Receptor, TRAIL-2; Receptor, TRAIL-4; Receptors, Tumor Necrosis Factor, Member 10a; Receptors, Tumor Necrosis Factor, Member 10d; TNF-Related Apoptosis-Inducing Ligand Receptor 2; TRAIL Receptor 1; TRAIL Receptor 2; TRAIL Receptor 4; TRAIL Receptors; Tumor Necrosis Factor Receptor Superfamily, Member 10a; Tumor Necrosis Factor Receptor Superfamily, Member 10b; Death Receptor 4; Death Receptor 5; Receptor 4, TRAIL; Receptor, APO2; Receptor, DCR2; Receptor, DR4; Receptor, DR5; Receptor, TRAIL 1; Receptor, TRAIL 2; Receptor, TRAIL 4; Receptor-4, Death; Receptors, TNF Related Apoptosis Inducing Ligand; TNF Related Apoptosis Inducing Ligand Receptor 2; TNF Related Apoptosis Inducing Ligand Receptors; TRAIL-1 Receptor; TRAIL-2 Receptor; TRAIL-4 Receptor; Decoy Receptor 2, Tumor Necrosis Factor; Receptors, TRAIL; Receptors, Tumor Necrosis Factor, Member 10; Receptors, Tumor Necrosis Factor, Member 10b; Tumor Necrosis Factor Receptor Superfamily, Member 10

Networked: 570 relevant articles (15 outcomes, 73 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 90489
  - Membrane Proteins: 5300
    - Cell Surface Receptors: 753
      - Death Domain Receptors: 502
        TNF-Related Apoptosis-Inducing Ligand Receptors: 570
        mouse Tnfrsf10b protein: 1
        human TNFRSF10B protein
        rat soluble tumor necrosis factor-related apoptosis-inducing ligand (114-281)
        rat Tnfrsf10b protein
      - Immunologic Receptors: 8
        Cytokine Receptors: 788
        Tumor Necrosis Factor Receptors: 2575
        TNF-Related Apoptosis-Inducing Ligand Receptors: 570
        mouse Tnfrsf10b protein: 1
        human TNFRSF10B protein
        rat soluble tumor necrosis factor-related apoptosis-inducing ligand (114-281)
        rat Tnfrsf10b protein

Experts

1.	Sun, Shi-Yong: 17 articles (12/2015 - 10/2004)
2.	Sakai, Toshiyuki: 15 articles (02/2014 - 08/2004)
3.	Khuri, Fadlo R: 14 articles (12/2015 - 10/2004)
4.	Liu, Xiangguo: 14 articles (11/2015 - 10/2004)
5.	Yue, Ping: 13 articles (12/2015 - 10/2004)
6.	Yagita, Hideo: 13 articles (11/2013 - 02/2004)
7.	Buchsbaum, Donald J: 12 articles (04/2011 - 04/2006)
8.	Horinaka, Mano: 11 articles (02/2014 - 08/2004)
9.	Yoshida, Tatsushi: 10 articles (01/2014 - 08/2004)
10.	Kim, Yong-Sung: 9 articles (06/2013 - 08/2007)

Related Diseases

1.	Neoplasms (Cancer) 05/15/2010 - "In this study, we have attempted to further improve the CTL induction and potent antitumor efficacy of a combination mAb-based therapy (termed "trimAb therapy") that comprises tumor cell death-inducing anti-death receptor 5 mAb and immune activating anti-CD40 and anti-CD137 mAbs. " 01/01/2014 - "In conclusion, targeting the UPS may represent a novel strategy to increase the cell surface expression of pro-apoptotic TRAIL-R on cancer cells and should be considered in clinical trials targeting TRAIL-receptors in cancer patients. " 01/01/2012 - "Failure to achieve therapeutic effects in recent clinical trials using TRAIL-receptors targeting compounds might be due to insufficient selection of patients bearing tumors with membrane-bound TRAIL-receptors." 09/01/2011 - "Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors." 09/01/2010 - "In this study, we report that death receptor 5 (DR5) is enriched in pancreatic CSCs compared with the bulk of the tumor cells. "
2.	Carcinoma (Carcinomatosis) 05/01/2007 - "Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model." 01/01/2015 - "The combination treatment further increases the sensitivity of carcinoma cells to apoptosis through FAS and TRAIL receptors but does not change the sensitivity of normal non-malignant epithelial cells. " 01/01/2014 - "Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population." 12/01/2010 - "The majority of primary pancreatic carcinoma samples and all cell lines express one or both agonistic TRAIL receptors. " 12/01/2010 - "TRAIL-induced apoptosis is preferentially mediated via TRAIL receptor 1 in pancreatic carcinoma cells and profoundly enhanced by XIAP inhibitors."
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/2015 - "Mansoor et al reported that GG genotype in death receptor 4 played protective role however, CC genotype had a causative role in colorectal cancer in Pakistani population. " 12/01/2011 - "Coexpression of activated c-Met and death receptor 5 predicts better survival in colorectal carcinoma." 02/01/2008 - "DR5 receptor mediates anoikis in human colorectal carcinoma cell lines." 10/01/2006 - "Death receptor 4 variants and colorectal cancer risk." 11/27/1998 - "Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas."
4.	Adenocarcinoma 03/01/2009 - "High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients." 03/01/2006 - "Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma." 01/01/2013 - "Applying tissue microarray (TMA) analysis, we performed an immunohistochemical assessment of TRAIL-receptors in surgical samples from 84 consecutive patients affected by pancreatic adenocarcinoma and in 26 additional selected specimens from patients with no lymph nodes metastasis at the time of surgery. " 02/01/2012 - "The goal of the study was to assess the efficacy of combined extracellular matrix metalloprotease inducer (EMMPRIN)- and death receptor 5 (DR5)-targeted therapy for pancreatic adenocarcinoma in orthotopic mouse models with multimodal imaging. " 08/01/2009 - "peruviana were shown to have a significant reversal effect on TRAIL resistance in human gastric adenocarcinoma cells, and real-time PCR showed that thevefolin (2) enhanced mRNA expression of death receptor 4 (DR4) and DR5. "
5.	Fever (Fevers) 05/01/2012 - "In this study, we evaluated the anti-tumor efficacy of humanized anti-death receptor 4 (DR4) antibody mapatumumab (Mapa) by comparing it with TRAIL in combination with hyperthermia. " 12/01/2012 - "In this study, we present a novel potent multimodality strategy comprising humanized death receptor 4 (DR4) antibody mapatumumab in combination with oxaliplatin and hyperthermia to treat human colon cancer cells. " 01/01/2013 - "Searching for the most clinically relevant approaches for treating colorectal metastatic disease by isolated hepatic perfusion (IHP), we developed the application of oxaliplatin concomitantly with hyperthermia and humanized death receptor 4 (DR4) antibody mapatumumab (Mapa), and investigated the molecular mechanisms of this multimodality treatment in human colon cancer cell lines CX-1 and HCT116 as well as human colon cancer stem cells Tu-12, Tu-21 and Tu-22. "

Related Drugs and Biologics

1.	Antibodies
2.	gemcitabine
3.	mapatumumab
4.	Immunoglobulin G (IgG)
5.	Death Domain Receptors
6.	lexatumumab
7.	Caspase 3 (Caspase-3)
8.	CD147 Antigens (Basigin)
9.	bevacizumab
10.	TNF-Related Apoptosis-Inducing Ligand

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration
3.	Therapeutics
4.	Radiotherapy
5.	Heterologous Transplantation (Xenotransplantation)